| (19) |
 |
|
(11) |
EP 2 390 315 A8 |
| (12) |
CORRECTED EUROPEAN PATENT APPLICATION |
|
Note: Bibliography reflects the latest situation |
| (15) |
Correction information: |
|
Corrected version no 1 (W1 A1) |
| (48) |
Corrigendum issued on: |
|
09.05.2012 Bulletin 2012/19 |
| (88) |
Date of publication A3: |
|
30.11.2011 Bulletin 2011/48 |
| (43) |
Date of publication: |
|
30.11.2011 Bulletin 2011/48 |
| (22) |
Date of filing: 14.07.2008 |
|
| (51) |
International Patent Classification (IPC):
|
|
| (84) |
Designated Contracting States: |
|
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MT NL NO PL
PT RO SE SI SK TR |
| (30) |
Priority: |
12.07.2007 US 959203
|
| (62) |
Application number of the earlier application in accordance with Art. 76 EPC: |
|
08796186.8 / 2167655 |
| (71) |
Applicant: NEW ENGLAND BIOLABS, INC. |
|
Ipswich, MA 01938-2723 (US) |
|
| (72) |
Inventors: |
|
- Zhu, Zhenyu
Beverly, MA 01915 (US)
- Blanchard, Aine
Wakefield, MA 01880 (US)
- Xu, Shuang-Yong
Lexington, MA 02420 (US)
- Guan, Shengxi
Ipswich, MA 01938 (US)
- Wei, Hua
New Brunswick, NJ 08901 (US)
- Zhang, Penghua
Lexington, MA 02421 (US)
- Sun, Dapeng
Arlington, MA 02474 (US)
- Chan, Siu-hong
Ipswich, MA 01938 (US)
|
| (74) |
Representative: Froud, Clive |
|
Clive Froud & Co Limited
7 Hurst Close
Tenterden
Kent TN30 6UG
Kent TN30 6UG (GB) |
|
| |
|
|
|
Remarks: |
|
This application was filed on 24-05-2011 as a divisional application to the application
mentioned under INID code 62. |
|
| (54) |
High fidelity restriction endonucleases |
(57) Inter alia, a composition characterized in that it comprises: a restriction endonuclease enzyme
having at least one artificially introduced mutation and an overall fidelity index
(FI) improvement factor of at least 2, the restriction endonuclease being capable
of cleaving a substrate with at least a similar cleavage activity to that of the restriction
endonuclease absent the artificially introduced mutation, in a predetermined buffer,
wherein the artificially introduced mutation is the product of at least one of a targeted
mutation, saturation mutagenesis, or a mutation introduced through a PCR amplification
procedure, and wherein the restriction endonuclease absent the artificially introduced
mutation is PvuII and the artificially introduced mutation is selected from: T46A;
T46H; T46K; T46Y; and T46G is disclosed.